Evaluation of effect of fluoxetine on the clinical prognosis in patients with Optic neuritis
- Conditions
- The Optic neuritis.Optic neuritis
- Registration Number
- IRCT20200719048138N1
- Lead Sponsor
- Iran University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 100
Iranian patients
Age over 18 years old
Patients diagnosed with Optic neuritis
History of multiple sclerosis
cataract, glaucoma ( open or close angle ) congenital eye diseases such as coloboma and involvement with other disorders effecting the central visual field
Patients with past medication history of using fluoxetine or other psychotherapeutics including antidepressants
psychological disease
medication history of arthemeter? astemizol, cisapride, eliglustat, goserelin, isocarboxazide, artemether, leuprolide, linezolid, lumefantrine, methylene blue, phenelzine, pimozide, procarbazine, selegiline, thioridazine, tranylcypromine
Patients diagnosed with autoimmune and collagen vascular diseases
Trauma or history of ophthalmologic surgeries
Interval between involvement and interview more than 3 weeks
Pregnancy
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 1)Visual acuity: precision of vision assessed by snelene chart. Timepoint: On first visit and 6th month after initiation of treatment. Method of measurement: Visual acuity: snelene chart.;VEP (Visual evoked potential) test: both time ( latency) and amplitude parameters of VEP test will measure. Timepoint: On first visit and 6th month after initiation of treatment. Method of measurement: VEP test by means of VEP device.
- Secondary Outcome Measures
Name Time Method OCT: thickness of retina. Timepoint: OCT: on first visit and 6th month after initiation of treatment. Method of measurement: OCT: OCT device.;Perimetry: percent of scotoma in visual field. Timepoint: Perimetry: On first visit and 6th month after initiation of treatment. Method of measurement: Perimetry: digital perimetry device.